Podcast
Rheumnow Podcast
Hosted by Dr. Cush · EN
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
82episodes
Episodes
Newest firstAll episodes
A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12
5d ago00:25:48Tap to summarizeDr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026. Learn how those findings impact their clinical decision-making. Sponsored by AbbVie Medical Affairs + Health Impact
Transcribe →
TU: Systemic Burden of Gout Part 2 (24 plus)
1w ago00:29:23Tap to summarizeDr. Jack Cush Obesity & Gout Dr. Tony Merriman Genome-Wide Association Studies in Gout Dr. Lisa Stamp Gout Management in Patients with Chronic Kidney Disease Dr. Mark Fisher Gout & Mortality
Transcribe →Methotrexate Safety Tips (7.31.2026)
1w ago00:20:16Tap to summarizeDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
Transcribe →
Gout Lessons from the Clinic Part 3
1w ago00:28:33Tap to summarizeDr. Sheila Reyes: QD Clinic: The Highs and Lows of a Woman with Gout Dr. Jack Cush QD319 A Watched Tophus Never Resolves Dr. Eric Dein QD316: Addressing Severe Gout Flares Dr. Janet Pope QD Clinic: RA Mimics — Two Cases That Turned Out to Be Gout
Transcribe →
DERM on RheumNow (July 2026)
1w ago00:10:39Tap to summarizeThe Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72 Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://buff.ly/TLjMy21 Guidelines to Spot Cancer in High Risk Dermatomyositis Psoriatic Arthritis: EULAR 2026
Transcribe →
New, Advanced Therapies in Gout
1w ago01:01:25Tap to summarizeNew, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)
Transcribe →Systemic Burden of Gout Part 1
1w ago00:34:09Tap to summarizeDr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology Dr. Nicola Dalbeth Outcomes of Tophaceous Gout Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?
Transcribe →
Better Gout Management
1w ago00:19:43Tap to summarizeDr. John Fitzgerald Gout & Metabolic syndrome Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity
Transcribe →Gout Advice & Tips
1w ago00:24:21Tap to summarizeDr. Robert Terkeltaub Four things you need to know about allopurinol hypersensitivity syndrome Dr. Angelo Gaffo Challenges in Gout Diagnosis Dr. Janet Pope Tips for safe use of allopurinol in patients with gout
Transcribe →Gout Lessons from the Clinic Part 2
1w ago00:30:59Tap to summarizeDr Janet Pope: QD Clinic: Can RA and Gout Manifest Simultaneously? Dr. Mrinalini Dey QD312: Gout, Sepsis… or Both? Daric Mueller, PA-C QD315: Pegloticase Immunomodulation: What’s on the Menu? Dr. Richard Conway: QD313: Don't Presume on IL-1 in Gout
Transcribe →